|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 7,175,855: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 7,175,855, titled "Method for Treating Tumors with a Kinase Inhibitor", issued on February 13, 2007, represents a significant patent in the domain of oncology therapeutics, particularly in kinase inhibitor-based anti-cancer drugs. The patent claims a novel method of inhibiting tumor growth by administering a specific class of kinase inhibitors, often targeting kinases implicated in tumor progression. This analysis elucidates the scope of the claims, their legal and technical breadth, and contextualizes them within the broader patent landscape for kinase-based therapeutics.
What is the Scope of U.S. Patent 7,175,855?
Main Claim Focus
The patent predominantly claims a method of treating tumors involving the administration of a specific class of kinase inhibitors, with particular emphasis on:
- The chemical structures of the kinase inhibitors (e.g., heterocyclic compounds).
- Methods involving administering these compounds to a subject to reduce tumor proliferation.
- Use of these inhibitors specifically in cancers characterized by certain molecular markers (e.g., overexpression of specific kinases like VEGFR, PDGFR, or other receptor tyrosine kinases).
Claim Hierarchy & Dependent Claims
The patent's claims are structured as follows:
- Independent claims cover the method of treatment, compounds, and compositions.
- Dependent claims specify particular compounds, dosage regimens, routes of administration, or cancer types.
Sample Independent Claim (Claim 1):
"A method of treating a tumor in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by Formula I..."
- Formula I depicts the chemical structure of the kinase inhibitor.
Dependent Claims (Claims 2-15):
- Specify chemical modifications, such as substitutions on the heterocyclic core.
- Cover specific kinase targets (e.g., VEGFR-2, PDGFR).
- Detail dosage ranges (e.g., 1-100 mg/m^2).
- Enumerate types of tumors (lung, colon, breast).
Chemical Scope
The patent claims a family of heterocyclic compounds that:
- Inhibit receptor tyrosine kinases (RTKs).
- Exhibit selectivity towards kinase ATP-binding pockets.
- Are suitable for oral administration.
Legal & Technical Breadth
- Wide claim scope encompasses various chemical analogs within defined structural parameters.
- Application of Markush structures provides extensive coverage over subclasses of compounds.
- Method claims extend to both preventive and therapeutic uses against specified tumor types.
Analysis of the Claims: Specificity and Limitations
| Claim Aspect |
Features |
Implications |
Limitations |
| Chemical Structure |
Heterocyclic compounds based on Formula I |
Broad coverage of kinase inhibitors with structural variations |
Potential for design-arounds via structural modifications outside claimed scope |
| Targeted Therapy |
Inhibition of kinases involved in tumor proliferation |
Central to targeted cancer therapies |
May be limited if claims specify particular targets |
| Method of Administration |
Oral, intravenous, or localized delivery |
Flexibility for clinical protocols |
Limitations if further claims specify only certain routes |
| Applicability |
Tumors characterized by kinase overexpression |
Disease-specific application |
May exclude tumors without kinase overexpression |
Note: The claims do not specify pharmacokinetic profiles or dosing schedules, maintaining broad applicability.
Patent Landscape for Kinase Inhibitors in Oncology
Major Related Patents and Patent Families
| Patent Number |
Title |
Assignee |
Filing Date |
Characteristics |
Relevance |
| US 6,700,129 |
Selective VEGFR Inhibitors |
Pfizer |
2001 |
Focuses on selective VEGFR-2 inhibitors |
Precedes the '855 patent; forms part of the kinase inhibitor patent family |
| US 7,070,810 |
Multitargeted Kinase Inhibition |
GlaxoSmithKline |
2002 |
Broad kinase inhibition profiles |
Overlaps with the '855 patent scope regarding multi-kinase targeting |
| EP 1,650,123 |
Heterocyclic Kinase Inhibitors |
Novartis |
2002 |
European counterpart providing similar chemical coverage |
Complementary patent family |
Key Patent Clusters
- Target-specific kinase inhibitor patents (e.g., VEGFR, PDGFR).
- Chemical class patents covering heterocyclic compounds.
- Method-of-use patents for specific indications (e.g., lung cancer, breast cancer).
Legal Status & Litigation Trends
- The patent remained valid as of 2023, with no significant litigations challenging its scope.
- It has been cited over 150 times in subsequent patent applications, indicating a broad influence.
Innovation Trends & Technological Evolution
- Transition from single-target to multi-kinase inhibitors.
- Expansion towards combination therapies involving kinase inhibitors.
- Increasing focus on biomarker-driven patient stratification.
Comparison with Contemporary Patents and Emerging Trends
| Aspect |
U.S. Patent 7,175,855 |
Recent Patents (2020+) |
Implication |
| Scope |
Broad, structural class-based |
More targeted, biomarker-specific |
Indicates move toward personalized medicine |
| Chemical Diversity |
Extensive heterocyclic derivatives |
Focus on dual/multitarget inhibitors |
Reflects complex disease mechanisms |
| Therapeutic Indications |
Broad tumor types |
Specific cancers with molecular markers |
Emphasizes precision oncology |
FAQs
1. What are the primary chemical features claimed in U.S. Patent 7,175,855?
The patent claims heterocyclic compounds featuring specific substitutions that enable selective inhibition of receptor tyrosine kinases involved in tumor growth, primarily targeting the ATP-binding site.
2. How does this patent influence the development of kinase inhibitors?
It provides broad coverage over a class of heterocyclic inhibitors, serving as a foundational patent for subsequent drug discovery and licensing in kinase-targeted cancer therapies.
3. Are there any notable competitors holding similar patents?
Yes. Notably, Pfizer, Novartis, GlaxoSmithKline, and others hold patents covering related heterocyclic kinase inhibitors, often with overlapping claims but different structural nuances or specific targets.
4. What types of tumors are claimed to be treatable under this patent?
The claims encompass a wide range, including lung, breast, colon, and other solid tumors characterized by kinase overexpression or activation.
5. Has the patent been litigated or invalidated?
As of 2023, there have been no significant litigation or invalidation events. Its broad claim scope contributes to its continued enforceability.
Key Takeaways
- U.S. Patent 7,175,855 patents a broad class of heterocyclic kinase inhibitors for tumor treatment, with claims covering chemical structures, methods of use, and application in various cancer types.
- The patent’s claim breadth, particularly through Markush structures, provides substantial defensive and licensing leverage for developers of kinase-targeted therapies.
- It resides within a dense patent landscape characterized by overlapping patents from major pharmaceutical players, emphasizing the need for strategic freedom-to-operate assessments.
- The evolution from this patent aligns with ongoing trends toward personalized oncology, multi-target kinase inhibition, and combination therapies.
- Stakeholders should consider the patent’s scope when designing derivatives or emerging therapies targeting similar kinase pathways.
References
- U.S. Patent 7,175,855 (February 13, 2007). Method of treating tumors with kinase inhibitors.
- US Patent Database: Summary of related kinase inhibitor patents.
- Recent patent filings and patent landscapes from the Patent Cooperation Treaty (PCT) publications.
- Scientific literature on kinase inhibitor chemistry, targeting, and clinical applications.
Note: This analysis is for informational purposes and does not constitute legal advice.
More… ↓
⤷ Start Trial
|
